Morgan Stanley raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $462 from $459 and keeps an Equal Weight rating on the shares. The firm adjusted its large cap pharma and biotech models for IQVIA trends as well as intra-quarter updates ahead of Q1 earnings reporting season for the group.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals announces EC approval of expanded KAFTRIO label
- Early notable gainers among liquid option names on April 4th
- Vertex Pharmaceuticals price target raised to $420 from $408 at RBC Capital
- Marks’ Resignation Is a ‘Blow for Biotech Industry,’ Says RBC Analyst as Biotech Stocks Fall
- Biotech stocks slide as Marks resignation seen being negative for sector